SEB Fund 3 - SEB Medical Fund merges with SEB Concept Biotechnology 

The management company, SEB Investment Management, has decided to merge SEB Fund 3 - SEB Medical Fund with SEB Concept Biotechnology, the receiving fund. The merger will be carried out 21 April 2023.  

Affected unit classes and ISIN  

SEB Fund 3 - SEB Medical Fund (merging sub-fund)

SEB Concept Biotechnology (receiving fund)

The reason for the merger is to provide the benefit of a larger fund size which would result in greater efficiency from a portfolio management, operational, and cost-effective perspective.  

This is a merger by absorption, whereby the merging sub-fund's (SEB Fund 3 – SEB Medical Fund) holdings - assets and liabilities - will be transferred to the receiving fund (SEB Concept Biotechnology), and SEB Fund 3 - SEB Medical Fund will cease to exist. 

The merging sub-fund and the receiving fund have similar investment objectives and fundamental investment strategies and are managed by the same investment team. Therefore, the receiving fund will continue to follow the same investment objective and strategy as previously, and the fund’s fees will not be affected.  

If fund unit holders wish to redeem their units in either of the funds, units may be purchased or redeemed free of charge till 14 April 2023. SEB Investment Management AB bears any costs related to legal, advisory and administration costs that arise in relation to the merger. Redemption can result in taxation. 

For customers who have active Fund Standing order for subscription to the subfund, and do not want to have the Fund Standing order for subscription to the new fund, we kindly invite to terminate it no later than 14 April 2023, until 14:00, by submitting the order in the internet bank section Payments – Standing orders.

Additional information is available on the SEB group webpage.